TP53 and lung cancer: To further investigate the contribution of miR-128-2 modulation to mutant p53 gain of function activity, they assessed whether miR-128-2 exogenous expression impacts the response of H1299 lung cancer cell line to doxorubicin (DOXO), cisplatinum (CDDP), and 5-fluorouracil (5-FU).